Organogenesis Holdings (ORGO) EBITDA Margin (2017 - 2026)
Organogenesis Holdings (ORGO) posted quarterly EBITDA Margin of 185.05% for Q1 2026, down 15420.0% year-over-year from N/an in Q1 2025, and down 759.66% quarter-over-quarter from 28.05% in Q4 2025.
Organogenesis Holdings (ORGO) EBITDA Margin (2017 - 2026) Analysis & Trends
Organogenesis Holdings' EBITDA Margin history runs 10 years deep, the most recent figure standing at 185.05% for Q1 2026.
- In Q1 2026, EBITDA Margin fell 15420.0% year-over-year to 185.05%; the TTM figure through Mar 2026 stood at 0.5% (up 577.0% YoY), while the FY2025 annual figure was 7.92%, up 819.0% from the prior year.
- EBITDA Margin for Q1 2026 stood at 185.05%, down from 28.05% in the prior quarter.
- The five-year high for EBITDA Margin was 28.05% in Q4 2025, with the low at 185.05% in Q1 2026.
- The 5-year median for EBITDA Margin is 1.52% (2022), against an average of 9.28%.
- The sharpest annual moves came in 2025 and 2026: EBITDA Margin jumped 1998 bps in 2025, then plunged 15420 bps in 2026.
- Organogenesis Holdings' EBITDA Margin stood at 7.55% in 2022, then slumped by 117 bps to 1.27% in 2023, then surged by 734 bps to 8.07% in 2024, then jumped by 248 bps to 28.05% in 2025, then sank by 760 bps to 185.05% in 2026.
- Business Quant data shows ORGO's EBITDA Margin at 185.05% in Q1 2026, 28.05% in Q4 2025, and 13.74% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -5.58% |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 33.91% |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 16.51% |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 42.23% |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 0.17% |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 15.80% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 18.13% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Organogenesis Holdings | 238.69 Mn | 191.85 Mn | 20.08 Mn | -116.54% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -116.54% |
| Mar 31, 2026 | -185.05% |
| Dec 31, 2025 | 28.05% |
| Sep 30, 2025 | 13.74% |
| Jun 30, 2025 | -12.45% |
| Mar 31, 2025 | -30.85% |
| Dec 31, 2024 | 8.07% |
| Sep 30, 2024 | 5.42% |
| Jun 30, 2024 | -10.67% |
| Mar 31, 2024 | -3.50% |
| Dec 31, 2023 | -1.27% |
| Sep 30, 2023 | 7.42% |
| Jun 30, 2023 | 8.31% |
| Mar 31, 2023 | -3.72% |
| Dec 31, 2022 | 7.55% |
| Sep 30, 2022 | 1.52% |
| Jun 30, 2022 | 9.83% |
| Mar 31, 2022 | -0.13% |
| Dec 31, 2021 | 15.45% |
| Sep 30, 2021 | 14.30% |